A Director at Canterbury Park Holding Corp (NASDAQ: CPHC) is Selling Shares (AnalystRatings)
Today, a Director at Canterbury Park Holding Corp (CPHC), Burton Dahlberg, sold shares of CPHC for $9,700. CPHC’s market cap is $65.65M and the company has a P/E ratio of 11.47. Currently, Canterbury Park Holding Corp has an average volume of 293. The insider sentiment on Canterbury Park Holding Corp has been positive according to 11 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Wednesday 4/17 Insider Buying Report: HCI, MVC (Nasdaq.com)
At HCI Group (HCI), a filing with the SEC revealed that on Friday, Director Gregory Politis bought 4,000 shares of HCI, at a cost of $40.91 each, for a total investment of $163,620. HCI Group is trading down about 1.3% on the day Wednesday. And at MVC Capital (MVC), there was insider buying on Friday, by Chairman Michael T. Tokarz who purchased 2,100 shares at a cost of $9.20 each, for a total investment of $19,320. Before this latest buy, Tokarz made one other buy in the past year, purchasing $46,800 shares for a cost of $9.36 a piece. MVC Capital is trading off about 0.9% on the day Wednesday.
Some Charges Tossed in Case that Ensnared ex-Orioles Star (wtop.com)
SANTA ANA, Calif. (AP) — A federal judge has dismissed the criminal case against a man convicted of profiting off of insider information provided by ex-baseball star Doug DeCinces. The Orange County Register reports the judge on Monday tossed the case against David Parker. The judge previously noted that prosecutors’ case against Parker during the first trial appeared to be contradicted by the testimony of DeCinces, the government’s own witness, during the second trial. DeCinces, a former third baseman for the California Angels and Baltimore Orioles, was convicted of insider trading for a stock buy that earned him more than $1 million. He agreed to testify against another defendant, James Mazzo, in exchange for a shorter sentence.
3 Small Biotech Stocks With Insider Buying (Seeking Alpha)
The biotech sector is off to a very tough start this Wednesday in what feels like a lot of algorithmic trading as the market is flat, and there is not a lot of news around the sector to account for the drop. Just before noon EST, the SPDR Biotech ETF (XBI) is down some four percent. For those inclined to do some ‘bargain shopping’, here are three small-cap biotech names with recent and significant insider buying. Let’s start with Syros Pharmaceuticals (SYRS). A director scooped up $4 million in new shares at $7.50 apiece on April 9th. While this occurred during a secondary offering that raised some $70 million, it was notable as it was the first insider buying this equity has seen since January of 2018.
Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) Insider Trading Activity – Major Shareholder Sold 117,140 shares of Stock (Market Exclusive)
Insider Trading Activity For Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO): Bioventures Ltd Novartis , Major Shareholder of Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) reportedly Sold 117,140 shares of the company’s stock at an average price of 1.05 for a total transaction amount of $122,997.00.
